Welgene Biotech Co., Ltd. is a leading provider of instruments, reagents, and services in the life sciences field. The company has launched a number of innovative clinical products, including:
Array comparative genomic hybridization(Cytoscan) is a more sensitive and specific way to detect chromosomal abnormalities than traditional chromosome analysis. It can detect microdeletions and microduplications that are not visible under a microscope.
Exome sequencing(ACMG-59) is a high-throughput sequencing technique that can identify genetic variants in all protein-coding regions of the genome. Exome sequencing is used to diagnose a variety of genetic conditions, including rare diseases, inherited cancers, and developmental disorders.
Non-invasive prenatal testing(Welbaby) is a noninvasive way to screen for chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome. It is performed by analyzing free fetal DNA in maternal blood.
Welgene's products and services are in line with standards and have obtained a number of certifications, including TAF, TFDA/LDTS etc.. The company is committed to providing customers with high-quality clinical product services.